Evidence map›Paper›PMID 41222897›Full record

ArticleClinical journal of gastroenterology2026

Tocilizumab for steroid-refractory hemophagocytic syndrome after durvalumab and tremelimumab for advanced hepatocellular carcinoma.

Yuki Kanayama, Takeshi Hatanaka, Yoshiki Tanaka, Teruo Yoshinaga, Hiromasa Iino, Nahoko Hatsumi, Yuka Yoshida, Atsushi Naganuma, Satoru Kakizaki, Toshio Uraoka

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuki KanayamaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, 564-1 Kamishindenmachi, Maebashi, 371-0821, Japan.ORCID http://orcid.org/0000-0002-8639-5212
Takeshi HatanakaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, 564-1 Kamishindenmachi, Maebashi, 371-0821, Japan. hatanaka@qk9.so-net.ne.jp.ORCID http://orcid.org/0000-0003-3656-285X
Yoshiki TanakaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, 564-1 Kamishindenmachi, Maebashi, 371-0821, Japan.
Teruo YoshinagaDepartment of Gastroenterology, Gunma Saiseikai Maebashi Hospital, 564-1 Kamishindenmachi, Maebashi, 371-0821, Japan.
Hiromasa IinoDepartment of Hematology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
Nahoko HatsumiDepartment of Hematology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
Yuka YoshidaDepartment of Pathology, Gunma Saiseikai Maebashi Hospital, Maebashi, Japan.
Atsushi NaganumaDepartment of Gastroenterology, NHO Takasaki General Medical Center, Takasaki, Japan.ORCID http://orcid.org/0000-0003-0663-0102
Satoru KakizakiDepartment of Gastroenterology, NHO Takasaki General Medical Center, Takasaki, Japan.ORCID http://orcid.org/0000-0003-0224-7093
Toshio UraokaDepartment of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case report describes a man in his early 70 s who developed hemophagocytic syndrome following administration of durvalumab plus tremelimumab (Dur/Tre) for advanced hepatocellular carcinoma (HCC). The diagnosis was suspected based on fever and cytopenia, and confirmed by bone marrow aspiration and blood tests, including measurements of soluble interleukin-2 receptor and ferritin. The condition was refractory to steroid therapy but improved after the administration of tocilizumab. This is the first reported case of hemophagocytic syndrome occurring after Dur/Tre treatment for HCC. Furthermore, this case suggests that tocilizumab may be an effective therapeutic option for steroid-refractory hemophagocytic syndrome.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularLiver NeoplasmsLymphohistiocytosis, HemophagocyticAgedHumansMaleAntibodies, MonoclonalAntibodies, Monoclonal, HumanizeddurvalumabtocilizumabtremelimumabCytotoxic T-lymphocyte-associated protein 4Hemophagocytic lymphohistiocytosisImmune-mediated adverse eventsInterleukin-6Soluble interleukin-2 receptorTocilizumab

Identifiers

PMID41222897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.